ArticleNature structural & molecular biology2026
Mechanistic insights into phosphorylation-driven activation and therapeutic inhibition of human ATR-ATRIP.
Article in Nature structural & molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ATR-ATRIP complex regulates the DNA replication stress and is targeted in cancer therapy, but the molecular mechanisms of its activation and inhibition have remained unclear. Here, we present high-resolution cryo-electron microscopy structures of the human ATR-ATRIP complex in distinct functional states, including two ATPγS-bound precatalytic states, a Chk1-bound catalytic state, a TopBP1-bound activated catalytic state and four inhibitor-bound states with gartisertib, berzosertib, ceralasertib and elimusertib. These structures show that ATPγS binding alone can prime the ATR kinase catalytic center for catalysis and position Chk1 without major conformational rearrangements. TopBP1 engages the ATR-ATRIP HEAT-repeat scaffold to reorganize the dimer into a near-symmetric conformation that promotes ATR-ATRIP autophosphorylation and efficient Chk1 phosphorylation. Notably, the phosphorylated ATR-ATRIP complex remains active toward Chk1 after TopBP1 dissociation while adopting an asymmetric conformation, indicating that catalytic activity is compatible with both near-symmetric and asymmetric conformations. In addition, inhibitor-bound structures reveal how potent and selective ATR inhibition is achieved through multipocket engagement and exploitation of active-site conformational plasticity. Together, our findings provide a structural framework for understanding multiple routes of ATR activation and inhibition, offering insights for developing next-generation ATR-targeted cancer therapies.
Identifiers
42754753What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.